Integra LifeSciences Holdings Corp filed an updated investor presentation on September 8, 2026, intended for use with prospective lenders as the company plans to refinance its outstanding senior credit facility in 2026. The presentation highlights trailing twelve-month revenue of $1.6 billion and adjusted EBITDA of $337 million, representing a 20.5% margin. Key operational milestones include the Q2 2026 activation of a new Braintree, Massachusetts manufacturing site and an anticipated Q4 2026 relaunch of the SurgiMend product. The company reports net leverage has decreased to 4.1x from 4.5x at year-end 2025, with a target range of 2.5x to 3.5x. Integra LifeSciences Holdings Corp operates in the medical device industry, specializing in neurosurgery and regenerative tissue repair solutions.

Integra LifeSciences Holdings Corporation reported second quarter 2026 financial results on July 29, 2026. Total revenues were $418.8 million, a 0.8% increase from the prior year period. GAAP net income was $4.5 million, or $0.06 per diluted share, compared to a loss of $(484.1) million in the previous year. Adjusted earnings per diluted share were $0.56, up from $0.45. The company updated its full-year reported revenue guidance to $1.654 billion–$1.695 billion and reaffirmed adjusted EPS guidance of $2.40–$2.50. Net debt stood at $1.6 billion with a leverage ratio of 4.1x. Integra operates in the medical technology industry, specializing in neurosurgery and tissue reconstruction products.